TY  - JOUR
PY  - 2020//
TI  - Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a real-world chart review study
JO  - Revista brasileira de psiquiatria
A1  - De Berardis, Domenico
A1  - Fornaro, Michele
A1  - Anastasia, Annalisa
A1  - Vellante, Federica
A1  - Olivieri, Luigi
A1  - Rapini, Gabriella
A1  - Serroni, Nicola
A1  - Orsolini, Laura
A1  - Valchera, Alessandro
A1  - Department of Mental HealthCarano, Alessandro
A1  - Tomasetti, Carmine
A1  - Ventriglio, Antonio
A1  - Bustini, Massimiliano
A1  - Pompili, Maurizio
A1  - Serafini, Gianluca
A1  - Perna, Giampaolo
A1  - Iasevoli, Felice
A1  - Martinotti, Giovanni
A1  - di Giannantonio, Massimo
SP  - 317
EP  - 321
VL  - 42
IS  - 3
N2  - OBJECTIVE: Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major depressive disorder (MDD). However, non-response is common, often necessitating combination strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients with SSRI-resistant MDD. <br><br>METHODS: The charts of 36 adult outpatients with DSM-IV-TR MDD who had not achieved a response after at least 8 weeks of treatment with an SSRI were reviewed retrospectively. Subjects were treated with vortioxetine (5-20 mg/day) for 8 weeks added to the current SSRI. The main outcome measures were change from baseline in total Hamilton Scale for Depression (HAM-D) score and the rate of response (a 50% or greater reduction in HAM-D score and a Clinical Global Impression &#8208; Improvement module [CGI-I] score of 1 or 2 at endpoint). HAM-D scores &#8804; 7 were considered as remission. Additional outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Scale for Suicide Ideation (SSI). <br><br>RESULTS: 32 patients completed the 8 weeks of treatment. At 8 weeks, a significant reduction in HAM-D score was observed (p &#8804; 0.001), with response obtained by 41.7% and remission by 33.3% of patients. Significant reductions in SHAPS and SSI were also observed (p &#8804; 0.001 for both scales). <br><br>CONCLUSIONS: Adjunctive vortioxetine may be useful and well-tolerated in stage I treatment-resistant depression. However, the limitations of this study (such as small sample size, absence of randomization and control group, retrospective design, etc.) must be considered.<p /> <p>Language: en</p>
LA  - en
SN  - 1516-4446
UR  - http://dx.doi.org/10.1590/1516-4446-2019-0690
ID  - ref1
ER  -